Current Neurology and Neuroscience Reports Journal Impact Factor & Information

Publisher: Current Medicine Group

Journal description

The Current Reports journals were developed out of the recognition that specialists have increasing difficulty keeping up to date with the expanding volume of information published in their fields. Current Neurology and Neuroscience Reports provides in a systematic manner: 1. the views of experts on current advances in neurology and neuroscience in a clear and readable form; 2. selections of the most important papers from the great wealth of original publications, annotated by experts.

Current impact factor: 3.06

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 3.059
2013 Impact Factor 3.669
2012 Impact Factor 3.783
2011 Impact Factor 3.455
2010 Impact Factor 2.697
2009 Impact Factor 2.25
2008 Impact Factor 2.455

Impact factor over time

Impact factor

Additional details

5-year impact 3.10
Cited half-life 4.20
Immediacy index 0.33
Eigenfactor 0.01
Article influence 1.05
Website Current Neurology and Neuroscience Reports website
Other titles Current neurology and neuroscience reports (Online), Current neurology and neuroscience reports
ISSN 1534-6293
OCLC 46681109
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Current Medicine Group

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Author's pre-print on pre-print servers such as
    • Author's post-print on author's personal website immediately
    • Author's post-print on any open access repository after 12 months after publication
    • Publisher's version/PDF cannot be used
    • Published source must be acknowledged
    • Must link to publisher version
    • Set phrase to accompany link to published version (see policy)
    • Articles in some journals can be made Open Access on payment of additional charge
    • Reviewed 09 June 2014
    • 'Current Medicine Group' is an imprint of 'Springer Verlag (Germany)'
  • Classification
    ​ green

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Traumatic brain injury (TBI) is a common cause of morbidity and mortality in military life. Interest in military TBI has increased recently due to the conflicts in Iraq and Afghanistan. Certain types of TBI are relatively unique to the military, the most prominent being blast-related TBI. Blast-related mild TBI has been of particular concern in veterans from the most recent conflicts although controversy remains concerning its separation from post-traumatic stress disorder. TBI is also a risk factor for the later development of neurodegenerative diseases in which cognitive impairment is prominent putting veterans at risk for disorders including Alzheimer's disease and chronic traumatic encephalopathy. Recent evidence associating TBI with chronic cognitive impairment is reviewed in the context of its relevance to military veterans.
    Current Neurology and Neuroscience Reports 10/2015; 15(10):591. DOI:10.1007/s11910-015-0591-8
  • [Show abstract] [Hide abstract]
    ABSTRACT: The diagnostic hallmarks of hippocampal sclerosis (HS) are severe volume loss of the hippocampus, severe neuronal loss, and reactive gliosis involving primarily two especially vulnerable fields, CA1 and the subiculum. Occasionally, HS may be the only neuropathological change detected in older individuals with dementia and is known as pure HS. In the majority of cases, HS occurs in the setting of other degenerative changes, usually Alzheimer's disease (AD). In these cases, it is classified as combined HS. Although a clinical profile for HS has been identified, its similarities with AD make the diagnosis during life quite challenging; thus, the diagnosis is often made postmortem. The pathogenesis of HS is not completely understood, but the strong association with transactive response DNA-binding protein 43 (TDP-43), in approximately 90 %, and the recent discovery of genetic risk factors are important contributions to a better understanding of the disease process.
    Current Neurology and Neuroscience Reports 10/2015; 15(10):592. DOI:10.1007/s11910-015-0592-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: Super-refractory status epilepticus (SRSE) is a devastating neurological condition with limited treatment options. We conducted an extensive literature search to identify and summarize the therapeutic options for SRSE. The search mainly resulted in case reports of various pharmacologic and non-pharmacologic treatments. The success rate of each of the following agents, ketamine, inhaled anesthetics, intravenous immunoglobulin G (IVIG), IV steroids, ketogenic diet, hypothermia, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and vagal nerve stimulation (VNS), are discussed in greater detail. The choice of appropriate treatment options for a given patient is based on clinical presentation. This review focuses on evidence-based, pharmacotherapeutic strategies for patients in SRSE.
    Current Neurology and Neuroscience Reports 10/2015; 15(10):589. DOI:10.1007/s11910-015-0589-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neurological disorders secondary to single gene mutations are an extremely heterogeneous group of diseases, individually rare, and often associated with progressive and severe disability. Given the degree of both clinical and genetic heterogeneity, next-generation sequencing (NGS) has become an important diagnostic tool. Multi-gene panel testing based on NGS is now prominently used, while whole-exome sequencing and whole-genome sequencing are emerging to facilitate the molecular diagnosis for many genetic neurological diseases. Although single-gene testing remains an important first tier test for disorders with clear phenotype-genotype correlation, NGS provides an expanding unbiased approach to identify rare mutations in genes known to be associated with genetically heterogeneous diseases, and those not initially considered by the clinician due to rarity or atypical clinical presentation. Given the decreasing costs and relatively rapid time to results, NGS-based assessment is quickly becoming a standard-of-care test for patients with genetic neurological diseases.
    Current Neurology and Neuroscience Reports 09/2015; 15(9):584. DOI:10.1007/s11910-015-0584-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review article focuses on the cognitive profile associated with the C9orf72 gene with GGGGCC (G4C2) hexanucleotide repeat expansions that is commonly found in both familial and sporadic forms of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) in order to aid clinicians in the screening process. In this growing clinical continuum between FTD and ALS, understanding and recognizing a neurocognitive profile is important for diagnosis. Key features of this profile include executive dysfunction with memory impairment and language deficits as the disease progresses. Behaviorally, patients are prone to disinhibition, apathy, and psychosis. With the discovery of this mutation, studies have begun to characterize the different phenotypes associated with this mutation in terms of epidemiology, clinical presentation, imaging, and pathology. Greater awareness and increased surveillance for this mutation will benefit patients and their families in terms of access to genetic counseling, research studies, and improved understanding of the disease process.
    Current Neurology and Neuroscience Reports 09/2015; 15(9):582. DOI:10.1007/s11910-015-0582-9
  • [Show abstract] [Hide abstract]
    ABSTRACT: Autoimmune disorders are increasingly recognized causes of several neurological disorders leading to significant clinical disability. This article reviews recent developments in our understanding on the pathophysiology, clinical presentations, and diagnoses of selected immune-mediated neurological disorders. It also provides a brief summary of current theories on autoimmunity and the role that certain environmental factors play in the development of immune-mediated neurological disorders. Recently recognized biomarkers might play a pathogenetic role or simply serve as a diagnostic tool.
    Current Neurology and Neuroscience Reports 09/2015; 15(9):581. DOI:10.1007/s11910-015-0581-x
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic kidney disease (CKD) is an increasing problem worldwide and is now being recognized as a global health burden particularly for cardiovascular and cerebrovascular events. The incidence of stroke increases in the presence of CKD with a 3-fold increased rate reported in ESRD. Atrial fibrillation (AF) increases the risk of stroke in CKD. There is conflicting observational evidence regarding benefit of anticoagulation in CKD for prevention of stroke in AF as risk of bleeding is high. Overall, anticoagulant in CKD may be beneficial in appropriate patients with meticulous monitoring of international normalized ratio (INR). Neurological manifestations related to electrolyte disorders, drug toxicity, and uremia are common in CKD. Appropriate drug dosing, awareness of potential side effects of medications, prompt diagnosis, and treatment are essential in preventing long-term morbidity and mortality.
    Current Neurology and Neuroscience Reports 08/2015; 15(8):577. DOI:10.1007/s11910-015-0577-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: The diagnostic criteria for multiple sclerosis (MS) rely on clinical, paraclinical, and radiographic findings of limited specificity. Many disorders mimic MS, and the decision of when to investigate an alternative diagnosis can be challenging. Reliance on extensive ancillary testing to exclude potential mimics, however, is unnecessary in most cases. Rather, recognition and rigorous interpretation of "classic" clinical and radiographic features of MS are often sufficient to establish the diagnosis. Misinterpretation of the clinical and radiographic diagnostic criteria for MS in the setting of more common diseases and syndromes and a lack of vigilance for "red flags" are important contributors to misdiagnosis. A clinical framework for the differential diagnosis of MS that emphasizes phenotypes atypical for MS and suggests diseases or syndromes in which they more commonly occur may be an important diagnostic guide for clinicians in contemporary practice.
    Current Neurology and Neuroscience Reports 08/2015; 15(8):576. DOI:10.1007/s11910-015-0576-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: The combination of novel imaging techniques with the use of small animal models of disease is often used in attempt to understand disease mechanisms, design potential clinical biomarkers and therapeutic interventions, and develop novel methods with translatability to human clinical conditions. However, it is clear that most animal models are deficient when compared to the complexity of human diseases: they cannot sufficiently replicate all the features of multisystem disorders. Furthermore, some practical differences may affect the use or interpretation of animal imaging to model human conditions such as the use of anesthesia, various species differences, and limitations of methodological tools. Nevertheless, imaging animal models allows us to dissect, in interpretable bits, the effects of one system upon another, the consequences of variable neuronal losses or overactive systems, the results of experimental treatments, and we can develop and validate new methods. In this review, we focus on imaging modalities that are easily used in both human subjects and animal models such as positron emission and magnetic resonance imaging and discuss aging and Parkinson's disease as prototypical examples of preclinical imaging studies.
    Current Neurology and Neuroscience Reports 08/2015; 15(8):571. DOI:10.1007/s11910-015-0571-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transcranial magnetic stimulation (TMS) is a non-invasive method where an externally placed, rapidly changing magnetic field causes induction of weak electric currents that lead to changes in neuronal polarization and activity. TMS is a modality that has emerged as a unique tool in the study of functional neuroscience for several reasons. TMS can be used to selectively activate or inhibit specific cortical structures, leading to transient perturbations in their function. Systematic study of these perturbations has been employed to determine the function of specific cortical structures and to investigate structure-function relationships. These studies extend to the functional mapping of brain structures as well as brain networks. While TMS was first validated in studies of motor cortex function, it has been applied to the study of cognition and cognitive processing. "Virtual lesions" can be transiently induced in areas of eloquent cortex that allow for the evaluation of their function in cognition and behavior and can be used to evaluate the modes and hierarchy of control of these functions. When TMS is delivered in a repetitive fashion, long-term alterations of cortical function are induced which can be used to study functional brain plasticity, and the changes in brain plasticity in different cognitive states, including aging and diseases involving cognition. Furthermore, repetitive TMS strategies have been developed as possible modulators of cognitive function, with potential to serve as cognitive enhancers in both healthy and disease states. In this review, specific attention is given to the use of TMS in the evaluation of neurophysiologic changes in Alzheimer's disease (AD), as well as the potential role of TMS as a cognitive enhancing therapy in AD.
    Current Neurology and Neuroscience Reports 08/2015; 15(8):575. DOI:10.1007/s11910-015-0575-8
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since the advent of in vivo imaging, first with CT, and then MRI, structural neuroimaging in patients has been widely used as a tool to explore the neural correlates of a wide variety of cognitive functions. Findings from studies using this methodology have formed a core component of current accounts of cognition, but there are a number of problematic issues related to inferring cognitive functions from structural imaging data in stroke and more generally, lesion-based neuropsychology as a whole. This review addresses these concerns in the context of spatial neglect, a common disorder most frequently encountered following right hemisphere stroke. Recent literature, including attempts to address some of these questions, is discussed. Novel approaches and findings from related fields that may help to put stroke-based lesion mapping studies into perspective are reviewed, allowing critical but constructive evaluation of previous work in the field.
    Current Neurology and Neuroscience Reports 08/2015; 15(8):570. DOI:10.1007/s11910-015-0570-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic inflammatory demyelinating polyneuropathy (CIDP) is one of the acquired demyelinating neuropathies and is considered to be immune mediated. Diagnosis is typically based on clinical history, neurologic examination, electrophysiologic studies, CSF studies, and pathologic examination. Early diagnosis and treatment is important to prevent irreversible axonal loss and optimize improvement in function. The first-line agents for treatment are intravenous immunoglobulin (IVIg), corticosteroids, and plasmapheresis, which have all been demonstrated to be effective in controlled studies. Studies have not shown a significant difference between these three treatments, and the initial choice of therapy is often based on availability, cost, ease of administration, and side effect profile. If patients do not respond to one of these agents, they may respond to one of the others and sometimes in combination. If the first-line agents are not effective, chemotherapeutic or immunosuppressive agents may be considered. There are limited controlled studies of these modalities, and they are often used in conjunction with a first-line treatment. The majority of patients require long-term therapy to maintain a response and to prevent relapse.
    Current Neurology and Neuroscience Reports 07/2015; 15(7). DOI:10.1007/s11910-015-0563-z